TY - JOUR
T1 - Applicability and usage of dose mapping/accumulation in radiotherapy
AU - Murr, Martina
AU - Brock, Kristy K.
AU - Fusella, Marco
AU - Hardcastle, Nicholas
AU - Hussein, Mohammad
AU - Jameson, Michael G.
AU - Wahlstedt, Isak
AU - Yuen, Johnson
AU - McClelland, Jamie R.
AU - Vasquez Osorio, Eliana
N1 - Funding Information:
Kristy Brock reports funding from NIH/NCI under award number P30CA016672, NIH/NCI under award number 1R01CA221971, NIH/NCI under award number P01CA261669, a generous gift from the Apache Corporation, the Helen Black Image Guided Fund, and support from the Image Guided Cancer Therapy Research Program at The University of Texas MD Anderson Cancer Center.
Funding Information:
Mohammad Hussein was supported by the National Measurement System of the UK’s Department for Business, Energy and Industrial Strategy.
Funding Information:
Isak Wahlstedt reports funding from ViewRay and the Danish Comprehensive Cancer Center.
Funding Information:
Jamie McClelland acknowledges funding from CRUK via the Network Accelerator Award Grant (A21993) to the ART-NET consortiumand the Wellcome/EPSRC Centre for Interventional and Surgical Sciences (WEISS) (203145/Z/16/Z).
Funding Information:
Kristy Brock reports funding from RaySearch Laboratories AB through a Co-Development and Collaboration Agreement and a licensing agreement with RaySearch Laboratories AB.
Funding Information:
Martina Murr reports funding from DFG ZI 736/2–1 and MU 6403/1–1 (PAK 997/1–1).
Publisher Copyright:
© 2023 The Author(s)
PY - 2023/5
Y1 - 2023/5
N2 - Dose mapping/accumulation (DMA) is a topic in radiotherapy (RT) for years, but has not yet found its widespread way into clinical RT routine. During the ESTRO Physics workshop 2021 on “commissioning and quality assurance of deformable image registration (DIR) for current and future RT applications”, we built a working group on DMA from which we present the results of our discussions in this article. Our aim in this manuscript is to shed light on the current situation of DMA in RT and to highlight the issues that hinder consciously integrating it into clinical RT routine. As a first outcome of our discussions, we present a scheme where representative RT use cases are positioned, considering expected anatomical variations and the impact of dose mapping uncertainties on patient safety, which we have named the DMA landscape (DMAL). This tool is useful for future reference when DMA applications get closer to clinical day-to-day use. Secondly, we discussed current challenges, lightly touching on first-order effects (related to the impact of DIR uncertainties in dose mapping), and focusing in detail on second-order effects often dismissed in the current literature (as resampling and interpolation, quality assurance considerations, and radiobiological issues). Finally, we developed recommendations, and guidelines for vendors and users. Our main point include: Strive for context-driven DIR (by considering their impact on clinical decisions/judgements) rather than perfect DIR; be conscious of the limitations of the implemented DIR algorithm; and consider when dose mapping (with properly quantified uncertainties) is a better alternative than no mapping.
AB - Dose mapping/accumulation (DMA) is a topic in radiotherapy (RT) for years, but has not yet found its widespread way into clinical RT routine. During the ESTRO Physics workshop 2021 on “commissioning and quality assurance of deformable image registration (DIR) for current and future RT applications”, we built a working group on DMA from which we present the results of our discussions in this article. Our aim in this manuscript is to shed light on the current situation of DMA in RT and to highlight the issues that hinder consciously integrating it into clinical RT routine. As a first outcome of our discussions, we present a scheme where representative RT use cases are positioned, considering expected anatomical variations and the impact of dose mapping uncertainties on patient safety, which we have named the DMA landscape (DMAL). This tool is useful for future reference when DMA applications get closer to clinical day-to-day use. Secondly, we discussed current challenges, lightly touching on first-order effects (related to the impact of DIR uncertainties in dose mapping), and focusing in detail on second-order effects often dismissed in the current literature (as resampling and interpolation, quality assurance considerations, and radiobiological issues). Finally, we developed recommendations, and guidelines for vendors and users. Our main point include: Strive for context-driven DIR (by considering their impact on clinical decisions/judgements) rather than perfect DIR; be conscious of the limitations of the implemented DIR algorithm; and consider when dose mapping (with properly quantified uncertainties) is a better alternative than no mapping.
KW - Anatomical changes
KW - Deformable image registration (DIR)
KW - DIR uncertainties
KW - Dose mapping/accumulation
KW - Dose mapping/accumulation landscape (DMAL)
KW - Impact of dose mapping uncertainties
UR - http://www.scopus.com/inward/record.url?scp=85149360497&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85149360497&partnerID=8YFLogxK
U2 - 10.1016/j.radonc.2023.109527
DO - 10.1016/j.radonc.2023.109527
M3 - Review article
C2 - 36773825
AN - SCOPUS:85149360497
SN - 0167-8140
VL - 182
JO - Radiotherapy and Oncology
JF - Radiotherapy and Oncology
M1 - 109527
ER -